Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dermatophagoides allergenic extract
- Development stage
- Unknown
- Lead developer
- Lofarma
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Percutaneous, Subcutaneous, Sublingual, Intradermal
01
Overview
Dermatophagoides allergenic extract is a biological product derived from house dust mites of the genus *Dermatophagoides*, primarily *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*. Developed by LOFARMA S.p.A., it is utilized for both the diagnosis and treatment of respiratory allergies, such as allergic rhinitis and allergic asthma. The extract functions by interacting with allergen-specific IgE antibodies on the surface of mast cells and basophils; in diagnostic skin prick testing, this interaction triggers the release of inflammatory mediators like histamine. In the context of allergen-specific immunotherapy (AIT), the extract is administered to modulate the patient's immune response, inducing long-term desensitization and immune tolerance. The product has been evaluated in Phase 2 in-vivo biological standardization studies to define its activity in histamine equivalent prick (HEP) units.
- Other names
- House dust mite allergenic extractDermatophagoides pteronyssinus and Dermatophagoides farinae extractHDM allergenic extractHouse dust mite extract
02
Targets
BCR (Immunoglobulin G B Cell Receptor)House dust mite allergen-specific T-cell receptor (HDM-specific TCR)FcγRIIb (Low affinity immunoglobulin gamma Fc receptor IIb)pMHC-II (Peptide-major histocompatibility complex class II complex)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on dermatophagoides allergenic extract.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dermatophagoides allergenic extract.